Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Pamela A. Crilley"'
Autor:
Pam K. Mangat, Suanna S. Bruinooge, Timothy L. Cannon, Sagun Shrestha, Nicole L. Butler, Julie Gottlieb Fisher, Andrew L. Rygiel, Sasha L. Warren, Damien Hansra, Carmen Julia Calfa, Richard L. Schilsky, Ajjai Alva, Eugene R Ahn, Susan Halabi, Maged F. Khalil, Shamika Ranasinghe, Pamela A. Crilley, Elizabeth Garrett-Mayer, Kaitlyn R. Antonelli, Derrick S. Haslem
Publikováno v:
Journal of Clinical Oncology. 39:2443-2451
PURPOSE The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d11946030606eb338dcd7d63df0e61
https://doi.org/10.1200/jco.20.02923
https://doi.org/10.1200/jco.20.02923
Autor:
Daniel Haggstrom, Pam K. Mangat, Susan Halabi, Ramya Thota, Anu G. Gaba, Kathryn B. Alguire, Elie G. Dib, Samiha Islam, Andrew L. Rygiel, Richard L. Schilsky, Elizabeth Garrett-Mayer, Eugene R Ahn, Kaitlyn R. Antonelli, Ashish Sangal, Pamela A. Crilley, Alissa S. Marr, Suanna S. Bruinooge, Carmen Julia Calfa, Timothy L. Cannon
Publikováno v:
JCO Precision Oncology. :757-766
PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ebd8ac56b9a652d3f8c3c3e769fbde8
https://doi.org/10.1200/po.20.00037
https://doi.org/10.1200/po.20.00037
Autor:
Timothy L. Cannon, Ramya Thota, Nicole D. Fleming, Susan Halabi, Ricardo H. Alvarez, Jared Addison Cotta, Pam K. Mangat, Carmen Julia Calfa, Pamela A. Crilley, Sasha L. Warren, Andrew L. Rygiel, Theodore Pollock, Dan Veljovich, Elizabeth Garrett-Mayer, Julian C. Schink, Tareq Al Baghdadi, Julie Gottlieb Fisher, David Tait, Richard L. Schilsky
Publikováno v:
Targeted Oncology. 15:733-741
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb8f26ee6714134e4308f039853e6ab7
https://doi.org/10.1007/s11523-020-00753-7
https://doi.org/10.1007/s11523-020-00753-7
Autor:
Eugene R, Ahn, Pam K, Mangat, Elizabeth, Garrett-Mayer, Susan, Halabi, Elie G, Dib, Daniel E, Haggstrom, Kathryn B, Alguire, Carmen J, Calfa, Timothy L, Cannon, Pamela A, Crilley, Anu G, Gaba, Alissa S, Marr, Ashish, Sangal, Ramya, Thota, Kaitlyn R, Antonelli, Samiha, Islam, Andrew L, Rygiel, Suanna S, Bruinooge, Richard L, Schilsky
Publikováno v:
JCO precision oncology. 4
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::22f6b97e4feb10b0bbcb104d18d767c3
https://pubmed.ncbi.nlm.nih.gov/35050752
https://pubmed.ncbi.nlm.nih.gov/35050752
Autor:
Edie Weller, Kaitlen Reyes, James J. Vredenburgh, Adam Boruchov, Kimberly Noonan, Paul G. Richardson, Rachid Baz, Jacob P. Laubach, Abdel Kareem Azab, Houry Leblebjian, Robert L. Schlossman, Irene M. Ghobrial, Frank G. Basile, Pamela A. Crilley, Kenneth C. Anderson, Patrick Henrick, Michael Constantine, Stacey Chuma, Nikhil C. Munshi, Kenneth H. Shain, Kalvis Hornburg, Claudia E. Paba-Prada, Philippe Armand, Diane Warren, Yuji Mishima, Lorenzo Trippa, Chia Jen Liu, Oksana Zavidij
Publikováno v:
American Journal of Hematology. 94:1244-1253
We tested the hypothesis that using CXCR4 inhibition to target the interaction between the tumor cells and the microenvironment leads to sensitization of the tumor cells to apoptosis. Eligibility criteria included multiple myeloma (MM) patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed54d4f29749ede44ac5a0056743b0db
https://doi.org/10.1002/ajh.25627
https://doi.org/10.1002/ajh.25627
Autor:
Julie G, Fisher, David, Tait, Elizabeth, Garrett-Mayer, Susan, Halabi, Pam K, Mangat, Julian C, Schink, Ricardo H, Alvarez, Dan, Veljovich, Timothy L, Cannon, Pamela A, Crilley, Theodore, Pollock, Carmen J, Calfa, Tareq, Al Baghdadi, Ramya, Thota, Nicole, Fleming, Jared A, Cotta, Andrew L, Rygiel, Sasha L, Warren, Richard L, Schilsky
Publikováno v:
Targeted oncology. 15(6)
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::16cb8801c3f29f43a01e6355655a7eb0
https://pubmed.ncbi.nlm.nih.gov/33090333
https://pubmed.ncbi.nlm.nih.gov/33090333
Autor:
Pamela A. Crilley, Phil Stephens, Ankur R. Parikh, Maurie Markman, Lee A. Albacker, Alexa B. Schrock, Vincent A. Miller, Siraj M. Ali
Publikováno v:
Lung Cancer: Targets and Therapy
In non-small-cell lung cancer (NSCLC) refractory to standard therapy and which lacks well-known oncogenic drivers, genomic profiling can still identify genomic alterations that may suggest potential sensitivity to targeted therapy. PTEN mutation in N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a302f2d07277a3020752d16120750c
http://europepmc.org/articles/PMC5963481
http://europepmc.org/articles/PMC5963481
Autor:
Becky Slawik, Pamela A. Crilley, Shirelle Clark, Amber Moran, Cynthia Lynch, Daniel W. Nixon, Maurie Markman, Vicki Doctor, Ankur R. Parikh, Damien Hansra, Eugene R Ahn
Publikováno v:
Journal of Clinical Oncology. 39:e13001-e13001
e13001 Background: The genomic landscape of female breast cancer is rapidly evolving partially owing to advancements in next generation sequencing (NGS). Here we report the genomic characteristics of female breast cancer patients with locally recurre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::433ff0e2fd76a675d1879308a0a91946
https://doi.org/10.1200/jco.2021.39.15_suppl.e13001
https://doi.org/10.1200/jco.2021.39.15_suppl.e13001
Autor:
Elizabeth Garrett-Mayer, Julie Gottlieb Fisher, Timothy L. Cannon, Pam K. Mangat, Ricardo H. Alvarez, Samiha Islam, Susan Halabi, Andrew L. Rygiel, Kaitlyn R. Antonelli, Theodore Pollock, Suanna S. Bruinooge, Richard L. Schilsky, Jared Addison Cotta, Pamela A. Crilley, Tareq Al Baghdadi
Publikováno v:
Cancer Research. 79:CT135-CT135
Background: The TAPUR Study is a phase II multi-basket study that evaluates the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations known to be drug targets. Results in two cohorts of BC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::194618e173e6ebce90130f501013c993
https://doi.org/10.1158/1538-7445.am2019-ct135
https://doi.org/10.1158/1538-7445.am2019-ct135
Autor:
Damien Mikael Hansra, Eugene R Ahn, John Edward McKnight, Haritha Pabbathi, Cynthia Lynch, Pamela A. Crilley, Ankur Rasik Parikh, Sramila Aithal, Amber Moran, Rebecca Rollins, Daniel W. Nixon, Maurie Markman, Ricardo H. Alvarez
Publikováno v:
Journal of Clinical Oncology. 37:1098-1098
1098 Background: MBC is a rare entity comprising less than 1% of breast cancers [Siegel RL 2017]. Due to the low incidence of MBC, information about the genomic landscape of MBC is lacking. Here we describe detailed pathologic and genomic characteris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db4716fc834f9a650a9214d911630610
https://doi.org/10.1200/jco.2019.37.15_suppl.1098
https://doi.org/10.1200/jco.2019.37.15_suppl.1098